Odyssey Health Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Odyssey Health is de winst gegroeid met een gemiddeld jaarlijks percentage van 33.6%, terwijl de Medical Equipment industrie de winst growing met 13.1% per jaar.

Belangrijke informatie

33.6%

Groei van de winst

36.0%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	n/a
Rendement op eigen vermogen	140.7%
Nettomarge	n/a
Laatste winstupdate	30 Apr 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Odyssey Health geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:ODYY Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Apr 24	11	3	0
31 Jan 24	11	4	0
31 Oct 23	-4	4	0
31 Jul 23	-6	5	0
30 Apr 23	-7	5	1
31 Jan 23	-9	7	1
31 Oct 22	-9	7	1
31 Jul 22	-8	7	1
30 Apr 22	-9	7	2
31 Jan 22	-19	6	2
31 Oct 21	-18	5	2
31 Jul 21	-17	5	2
30 Apr 21	-15	4	1
31 Jan 21	-4	3	0
31 Oct 20	-4	3	0
31 Jul 20	-4	4	0
30 Apr 20	-26	26	0
31 Jan 20	-25	25	0
31 Oct 19	-25	25	0
31 Jul 19	-23	23	0
30 Apr 19	0	0	0
31 Jan 19	0	0	0
31 Oct 18	0	0	0
31 Jul 18	0	0	0
30 Apr 18	0	0	0
31 Jan 18	0	0	0
31 Oct 17	0	0	0
31 Jul 17	0	0	0
30 Apr 17	0	0	0
31 Jan 17	0	0	0
31 Oct 16	0	0	0
31 Jul 16	0	0	0
30 Apr 16	0	0	0
31 Jan 16	0	0	0
31 Oct 15	0	0	0
31 Jul 15	0	0	0

Kwaliteitswinsten: ODYY heeft een grote eenmalige winst van $14.7M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th April, 2024.

Groeiende winstmarge: ODYY is in het verleden winstgevend geweest.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ODYY is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 33.6% per jaar laten groeien.

Versnelling van de groei: ODYY is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: ODYY is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment -sector ( 12.2% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 140.7% ) van ODYY wordt als uitstekend beschouwd.

Odyssey Health Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Odyssey Health, Inc. announced delayed annual 10-K filing

Odyssey Health, Inc. announced that it has received $0.3 million in funding

Odyssey Health, Inc. announced delayed 10-Q filing

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS

Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.

Odyssey Health, Inc. Appoints Jeffrey Conroy as Director

Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote

Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Odyssey Health, Inc., Annual General Meeting, Jan 12, 2023

Odyssey Health Inc. Announces Expansion of Executive Team

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing (Mad) Clinical Trial

Odyssey Health, Inc. Announces Positive Results from its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug

Odyssey Health, Inc. Names Vice Admiral (r) Timothy Szymanski to the Military Advisory Board

Odyssey Group International Announces Formation of Military Advisory Board

Odyssey Group International, Inc. Continues Enrollment of its First in Kind Human Clinical Trial of its Proprietary Drug Compound Intended to Treat Concussion

Odyssey Group International, Inc. Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Odyssey Group International, Inc. Approves to Start Human Trial to Treat Concussion

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion

Odyssey Group International, Inc. announced delayed 10-Q filing

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion

Odyssey Group International, Inc. Announces the Completion of the Food and Drug Administration (FDA) Required Toxicology Studies Designed to Support Clinical Trials with Prv-002

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Odyssey Group International, Inc. announced a financing transaction

Odyssey Group International, Inc. announced delayed annual 10-K filing

Odyssey Group International, Inc. announced that it expects to receive $10.6 million in funding from The EquiLux Group, LP, Lincoln Park Capital, LLC

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden